Halyard Health Inc (HYH) Receives Average Rating of “Buy” from Analysts
Halyard Health Inc (NYSE:HYH) has earned a consensus recommendation of “Buy” from the eight ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $49.00.
A number of equities analysts have issued reports on the company. Zacks Investment Research upgraded Halyard Health from a “hold” rating to a “buy” rating and set a $53.00 target price for the company in a report on Thursday, January 4th. ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. TheStreet upgraded Halyard Health from a “c+” rating to a “b” rating in a report on Monday, December 4th. Stifel Nicolaus reiterated a “buy” rating and set a $52.00 target price on shares of Halyard Health in a report on Friday, November 3rd. Finally, KeyCorp reiterated a “hold” rating on shares of Halyard Health in a report on Tuesday, October 17th.
Halyard Health (NYSE:HYH) traded up $0.55 during mid-day trading on Tuesday, reaching $48.45. The company’s stock had a trading volume of 264,487 shares, compared to its average volume of 201,717. The company has a market cap of $2,270.00, a PE ratio of 40.71, a PEG ratio of 2.51 and a beta of 1.76. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.19 and a current ratio of 2.13. Halyard Health has a 52-week low of $35.24 and a 52-week high of $50.99.
Several hedge funds and other institutional investors have recently made changes to their positions in HYH. Goldman Sachs Group Inc. grew its holdings in shares of Halyard Health by 242.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,864,646 shares of the medical instruments supplier’s stock valued at $73,244,000 after acquiring an additional 1,320,735 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Halyard Health by 19.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,133,049 shares of the medical instruments supplier’s stock valued at $123,067,000 after acquiring an additional 507,893 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Halyard Health by 41.2% in the 2nd quarter. Northern Trust Corp now owns 1,510,297 shares of the medical instruments supplier’s stock valued at $59,324,000 after acquiring an additional 440,639 shares in the last quarter. Macquarie Group Ltd. bought a new position in shares of Halyard Health in the 3rd quarter valued at about $19,063,000. Finally, Koch Industries Inc. bought a new position in shares of Halyard Health in the 2nd quarter valued at about $297,000. Institutional investors own 89.71% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2018/01/09/halyard-health-inc-hyh-receives-average-rating-of-buy-from-analysts.html.
Halyard Health Company Profile
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Stock Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related stocks with our FREE daily email newsletter.